{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-029582","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.833644+00:00","generated_at":"2026-06-04T02:53:57.318164+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BiomX reports FY2023 net loss $26.2M; completes APT acquisition and $50M financing","bullets":["FY2023 net loss $26.2M vs $28.3M prior year; R&D expenses $16.7M.","Completed acquisition of Adaptive Phage Therapeutics (March 2024), gaining BX211 for DFO.","Closed $50M private placement led by Deerfield and AMR Action Fund; used to fund BX004 and BX211 through key data readouts.","Cash, restricted cash and short-term deposits $15.9M at Dec 31, 2023; company states sufficient for 12 months post-financing.","BX211 Phase 2 DFO trial enrolled 32 of 45 patients; topline results expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-029582","json":"https://secwatch.observer/filing/0001213900-24-029582.json","markdown":"https://secwatch.observer/filing/0001213900-24-029582.md","text":"https://secwatch.observer/filing/0001213900-24-029582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/0001213900-24-029582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/ea0203239-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:53:57.318164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"775a69b07f428d45985a7a31b6130fd82ee48a4c","claim":"BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 3, 2024, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/0001213900-24-029582-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}